MANKIND

Mankind Pharma continues to deliver steady growth in domestic formulations with strong brand recall. Margins are improving with better product mix and operating leverage. Expansion into chronic therapies adds stability. The stock remains a solid mid-cap pharma play with lower regulatory risk compared to export-heavy peers.